GVGeorge P. Vlasuk

George P. Vlasuk

*This is an algorithmically generated author record based on publicly available information.

George P. Vlasuk has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 June 2003
      • Vol. 63  (11) , 2997-3000

    Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism.

    by Todd A Hembrough, Glenn M Swartz, Adonia Papathanassiu, George P Vlasuk, William E Rote, Shawn J Green, Victor S Pribluda

    An association between cancer and thrombosis has been recognized for more than a century. However, the manner by which tumor growth is regulated by coagulation in vivo remains unclear. To assess the role of coagulation on tumor growth, in vivo, we tested coagulation inhibitors specific for either tissue factor (TF)/factor VIIa (fVIIa) complexes or factor Xa (fXa) for antitumor activity. Here, we show that two inhibitors of TF/fVIIa, TF pathway inhibitor (TFPI) and the nematode anticoagulant protein rNAPc2, inhibit both primary and metastatic tumor growth in mice. In addition, we show that rNAPc2 is also a potent inhibitor of angiogenesis. In contrast, rNAP5, a second nematode anticoagulant protein that specifically inhibits fXa, does not exhibit antitumor activity. Because the hemostatic activity of TF/fVIIa is mediated through activation of fXa, these data suggest that proteolytic activity of TF/fVIIa promotes tumor growth and angiogenesis through a novel proangiogenic mechanism and independently of hemostasis.


  • Pharmacokinetics and anticoagulant properties of the factor VIIa-tissue factor inhibitor recombinant Nematode Anticoagulant Protein c2 following subcutaneous administration in man

    by Annette Bradbury, Lily Lopez-Kinninger, Sonia Colón, Peter Bergum, Steven Maki, William Rote, George Vlasuk

    Summary: Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) is a potent (Ki=10 pM), inhibitor of the factor VIIa/tissue factor (fVIIa/TF) complex that requires the prerequisite binding to zymogen or activated factor X (fX). In two double blind, placebo-controlled, sequential dose-escalation phase I studies, rNAPc2 was found to be safe and well tolerated following single and repeat subcutaneous administrations in healthy human male volunteers at doses ranging from 0.3 to 5 µg/kg. There was a dose-dependent elevation of the prothrombin time reaching almost 4-fold above the baseline value in the highest dose group that directly correlated with rNAPc2 plasma concentration. In contrast, there was little or no effect on the activated partial thromboplastin time, thrombin time or template bleeding time. The pharmacokinetic behavior of rNAPc2 revealed a dose-independent and prolonged elimination half-life (t1/2β) with a mean of >50 hours. A high affinity interaction between rNAPc2 and plasma fX was shown to be essential for the prolonged t1/2β in man using crossed immunoelectrophoresis and was confirmed by exploiting the considerably weaker interaction between rNAPc2 and bovine fX which resulted in an attenuated t1/2β of ~1.5 hours in calves. The accumulated data suggests that rNAPc2 is safe and well tolerated following repeat subcutaneous administrations at doses up to 5 µg/kg in healthy volunteers. In addition, the in vivofate of rNAPc2 in man appears to be governed by its high affinity interaction with circulating fX. This data supports the continued development of this novel anticoagulant for the prevention and treatment of acute thrombotic disorders.


  • Orally Effective CVS-1123 Prevents Coronary Artery Thrombosis in the Conscious Dog

    by Geoffrey R. Cousins, Gregory S. Friedrichs, Yuji Sudo, Sam S. Rebello, William E. Rote, George P. Vlasuk, Thomas G. Nolan, Christine Mendoza, Benedict R. Lucchesi

    Background We examined the oral efficacy of a direct thrombin inhibitor, CVS-1123 [(CH 3 CH 2 CH 2 ) 2 -CH-CO-Asp(OCH 3 )-Pro-Arg-CHO; MW, 575]. The object was to determine whether thrombin inhibition could reduce the incidence of occlusive coronary artery thrombosis in response to arterial wall injury. Methods and Results Arterial wall injury was induced in conscious dogs by a 150-μA anodal current applied to the intimal surface of the circumflex coronary artery 30 minutes after oral CVS-1123 (20 mg/kg every 8 hours for three doses; n=11) or placebo containing diluent (n=10). Dogs were monitored for 8 hours and at 24 hours. The coronary artery remained patent for 24 hours in 8 of 11 CVS-1123–treated dogs. All dogs (n=10) in the placebo group developed a sustained, occlusive arterial thrombus. Two hours after the initial oral dose, the plasma CVS-1123 concentration was 13±1 μg/mL, reaching a maximum of 15±1 μg/mL after the second dose and 4.4±0.5 μg/mL at 24 hours. Ex vivo platelet aggregation to γ-thrombin was inhibited and activated partial thromboplastin time was increased after treatment with CVS-1123 ( P <.05). Conclusions The direct thrombin inhibitor CVS-1123 is effective after oral administration in reducing the incidence of primary thrombus formation in an experimental model of arterial wall injury. Thrombin-specific inhibitors, such as CVS-1123, may be alternative antithrombotic agents in clinical settings in which heparin-associated thrombosis is a complicating factor or when long-term anticoagulation is required.


  • Isolation and Characterization of the Tsetse Thrombin Inhibitor: A Potent Antithrombotic Peptide from the Saliva of Glossina morsitans morsitans

    by Michael Cappello, David I. Pritchard, George P. Vlasuk, Barbara A. Furmidge, Peter W. Bergum, Serap Aksoy

    A potent and specific inhibitor of the human coagulation protease thrombin was identified in salivary gland extracts of the tsetse fly, Glossina morsitans morsitans, an important vector of African trypanosomiasis. This low molecular weight peptide (MW = 3,530 Da as determined by laser desorption mass spectrometry) was purified using a combination of size-exclusion chromatography and reverse-phase, high-performance liquid chromatography, respectively. Amino terminal sequencing of the purified protein reveals no homology to any previously identified serine protease inhibitor or naturally occurring anticoagulant. The tsetse thrombin inhibitor (TTI) is a stoichiometric inhibitor of thrombin, with an apparent equilibrium dissociation inhibitory constant of 584 × 10-15 M. In addition, it is also a potent inhibitor of thrombin-induced platelet aggregation. Like other hematophagous arthropods, tsetse flies appear to have evolved a novel protease inhibitor capable of antagonizing host hemostasis and facilitating blood feeding.